GDF15 Suppresses Lymphoproliferation and Humoral Autoimmunity in a Murine Model of Systemic Lupus Erythematosus

J Innate Immun. 2022;14(6):673-689. doi: 10.1159/000523991. Epub 2022 Apr 20.

Abstract

Growth and differentiation factor 15 (GDF15), a divergent member of the transforming growth factor-β superfamily, has been associated with acute and chronic inflammatory conditions including autoimmune disease, i.e., type I diabetes and rheumatoid arthritis. Still, its role in systemic autoimmune disease remains elusive. Thus, we studied GDF15-deficient animals in Fas-receptor intact (C57BL/6) or deficient (C57BL/6lpr/lpr) backgrounds. Further, lupus nephritis (LN) microdissected kidney biopsy specimens were analyzed to assess the involvement of GDF15 in human disease. GDF15-deficiency in lupus-prone mice promoted lymphoproliferation, T-, B- and plasma cell-expansion, a type I interferon signature, and increased serum levels of anti-DNA autoantibodies. Accelerated systemic inflammation was found in association with a relatively mild renal phenotype. Splenocytes of phenotypically overall-normal Gdf15-/- C57BL/6 and lupus-prone C57BL/6lpr/lpr mice displayed increased in vitro lymphoproliferative responses or interferon-dependent transcription factor induction in response to the toll-like-receptor (TLR)-9 ligand CpG, or the TLR-7 ligand Imiquimod, respectively. In human LN, GDF15 expression was downregulated whereas type I interferon expression was upregulated in glomerular- and tubular-compartments versus living donor controls. These findings demonstrate that GDF15 regulates lupus-like autoimmunity by suppressing lymphocyte-proliferation and -activation. Further, the data indicate a negative regulatory role for GDF15 on TLR-7 and -9 driven type I interferon signaling in effector cells of the innate immune system.

Keywords: Autoantibodies; Autoimmunity; Growth and differentiation factor 15; Inflammation; Lupus nephritis; Macrophages; Toll-like-receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoimmune Diseases*
  • Disease Models, Animal
  • Growth Differentiation Factor 15
  • Humans
  • Interferon Type I*
  • Ligands
  • Lupus Erythematosus, Systemic*
  • Mice
  • Mice, Inbred C57BL

Substances

  • Ligands
  • Interferon Type I
  • GDF15 protein, human
  • Growth Differentiation Factor 15

Grants and funding

The study was funded by the Deutsche Forschungsgemeinschaft (LE2621/6-1) and National Science Center, Poland Grants 2016/23/B/NZ6/00086 to ML. The ERCB-KFB was supported by the Else Kröner-Fresenius Foundation.